ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,372.64
0.03%
Dow Jones
39,671.04
-0.51%
Gold vs US Dollar
2,366.67
-0.64%
Brent Oil
82.42
1.09%
Bitcoin
69,690.41
0.85%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Tenax Therapeutics Inc (TENX)

  7. Tenax Therapeutics Inc (TENX) News

Tenax Therapeutics (TENX)

Tenax Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:TENX
DateTimeSourceHeadlineSymbolCompany
21/05/202422:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TENXTenax Therapeutics Inc
21/05/202422:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TENXTenax Therapeutics Inc
14/05/202421:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TENXTenax Therapeutics Inc
14/05/202414:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
14/05/202413:00GlobeNewswire Inc.Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:TENXTenax Therapeutics Inc
30/04/202412:30GlobeNewswire Inc.Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)NASDAQ:TENXTenax Therapeutics Inc
09/04/202413:30GlobeNewswire Inc.Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”NASDAQ:TENXTenax Therapeutics Inc
28/03/202412:30GlobeNewswire Inc.Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial ResultsNASDAQ:TENXTenax Therapeutics Inc
12/03/202412:30GlobeNewswire Inc.Tenax Therapeutics to Present at the 36th Annual Roth ConferenceNASDAQ:TENXTenax Therapeutics Inc
29/02/202414:00GlobeNewswire Inc.Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024NASDAQ:TENXTenax Therapeutics Inc
26/02/202421:31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
26/02/202421:31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
23/02/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
21/02/202421:32Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
21/02/202421:30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
20/02/202421:01Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TENXTenax Therapeutics Inc
20/02/202413:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
20/02/202413:30GlobeNewswire Inc.Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to LevosimendanNASDAQ:TENXTenax Therapeutics Inc
16/02/202416:28Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TENXTenax Therapeutics Inc
16/02/202400:36Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TENXTenax Therapeutics Inc
14/02/202419:58Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TENXTenax Therapeutics Inc
13/02/202421:32Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
12/02/202421:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
09/02/202422:00Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:TENXTenax Therapeutics Inc
08/02/202421:51Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
08/02/202413:16GlobeNewswire Inc.Tenax Therapeutics Announces Pricing of Approximately $9 Million Public OfferingNASDAQ:TENXTenax Therapeutics Inc
08/02/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TENXTenax Therapeutics Inc
08/02/202401:01GlobeNewswire Inc.Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)NASDAQ:TENXTenax Therapeutics Inc
06/02/202414:20Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
06/02/202413:56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TENX

Your Recent History

LSE
POS
Plexus
LSE
GCM
Gcm Resources
LSE
NG.
National Grid
LSE
ITV
Itv
LSE
YU.
Yu
LSE
AV.
Aviva
LSE
VAST
Vast Resources
LSE
BP.
Bp
LSE
SOLG
Solgold
LSE
AGL
Angle
LSE
TERN
Tern
LSE
SCE
Surface Transforms
LSE
AAZ
Anglo Asian Mining
LSE
NFDS
Northern Foods
LSE
GGP
Greatland Gold
LSE
LLOY
Lloyds Banking
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved